Acrotech Biopharma LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$7.1M
Doctors Paid
3,147
Transactions
7,126
2024 Total
$1.9M
Payment Breakdown by Category
Research$6.0M (84.5%)
Consulting$661,911 (9.4%)
Food & Beverage$95,836 (1.4%)
Travel$28,392 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.0M | 820 | 84.5% |
| Consulting Fee | $661,911 | 341 | 9.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $155,333 | 67 | 2.2% |
| Food and Beverage | $95,836 | 4,500 | 1.4% |
| Grant | $70,000 | 1 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $65,800 | 19 | 0.9% |
| Travel and Lodging | $28,392 | 89 | 0.4% |
| Education | $16,587 | 1,285 | 0.2% |
| Honoraria | $3,250 | 2 | 0.0% |
| Entertainment | $35.88 | 2 | 0.0% |
Payments by Type
Research
$6.0M
820 transactions
General
$1.1M
6,306 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 246-13651-302 | $3.0M | 0 | 409 |
| 246-13651-301 | $1.3M | 0 | 231 |
| MEDI-MM36-302 | $380,272 | 0 | 53 |
| CD20-Targeted Systemic Radio-immunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Low Grade Non-Hodgkin Lymphomas | $278,772 | 0 | 1 |
| IIS-BEL-009 | $135,016 | 0 | 9 |
| A Bayesian sequentially adaptive phase I/II trial to jointly optimize the administration schedule (s) and dose of Melphalan HCL for Injection (Propylene Glycol-Free melphalan) as a preparative regimen for autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma | $98,955 | 0 | 3 |
| SPI-BEL-301 | $77,692 | 0 | 3 |
| A multi-center, open-label phase 1b/2 study of inotuzumab ozogamicin and vincristine sulfate liposome in adult patients with relapsed/refractory B lineage acute lymphoblastic leukemia (B-ALL) | $76,275 | 0 | 3 |
| IIS-MEL-005 | $71,613 | 0 | 3 |
| A phase 2 single arm multicenter trail to evalaute the efficacy of the bite antibody Blincyto and vincristine sulfate liposmal injection Marqibo in adult subjects with relapsed refracatory philadelphia negative cd19 acute lymphoblastic leukemia | $63,732 | 0 | 1 |
| Global outcomes of single agents vs combination chemotherapy for patients with R/R peripheral T-cell and NK/T-cell lymphoma | $54,359 | 0 | 2 |
| IIS-BEL-021 | $54,359 | 0 | 2 |
| SPI-FOL-102 | $49,894 | 0 | 15 |
| IIS-ZEV-016 | $38,500 | 0 | 1 |
| T2012-002 Protocol Amendment #4 version Date 03-Dec-2021 A pilot study of Vincristine Sulfate Liposome injection(Marquibo) in combination with chemotherapy for children, adolescents and young adults with relapse of acute lymphoblastic leukemia IND 128316 | $33,750 | 0 | 1 |
| IIS-BEL-023 | $23,257 | 0 | 6 |
| IIS-FOL-001 | $22,919 | 0 | 1 |
| IIS-MEL-004 | $21,500 | 0 | 2 |
| IIS-MEL-003 | $17,394 | 0 | 5 |
| IIS-BEL-003 | $15,452 | 0 | 5 |
| Therapeutic outcomes of novel agents vs conventional chemotherapy in clinical trials in patients with newly diagnosed and R/R mature T and NK/T-cell lymphomas: a meta- analysis study | $13,000 | 0 | 1 |
| IIS-BEL-011 | $9,975 | 0 | 1 |
| IIS-BEL-012 | $9,958 | 0 | 4 |
| SPI-BEL-502 | $9,375 | 0 | 5 |
| A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo) in Combination with Bendamustine and Rituximab (BRiM) in Indolent non-Hodgkin Lymphoma (IIS-MAR-003) | $9,358 | 0 | 1 |
| SPI-BEL-107 | $9,200 | 0 | 1 |
| Lead-in and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine* (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma | $8,183 | 0 | 2 |
| IIS-BEL-P-001 | $5,239 | 0 | 3 |
| SPI-FOL-101 | $5,078 | 0 | 1 |
| AB-MM36-PA-HV 003 | $4,625 | 0 | 14 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Owen O'connor, Md, MD | Medical Oncology | New York, NY | $130,171 | $0 |
| Hayder Saeed, M.d, M.D | Hematology & Oncology | Tampa, FL | $38,313 | $0 |
| Francine Foss, Md, MD | Medical Oncology | New Haven, CT | $35,487 | $0 |
| Dr. Ahmed Sawas, M.d, M.D | Hematology & Oncology | New York, NY | $27,557 | $0 |
| Dr. Matthew Lunning, D.o, D.O | Internal Medicine | Omaha, NE | $25,315 | $0 |
| Mr. Stefan Barta, M.d, M.D | Hematology & Oncology | Philadelphia, PA | $23,298 | $0 |
| Dr. Andrei Shustov, Md, MD | Hematology & Oncology | Seattle, WA | $20,567 | $0 |
| John Reneau, Md, Phd, MD, PHD | Hematology | Columbus, OH | $18,874 | $0 |
| Dr. Christina Poh, M.d, M.D | Hematology & Oncology | Duarte, CA | $18,270 | $0 |
| Dr. Sanjay Kaul, M.d, M.D | Specialist | Los Angeles, CA | $14,400 | $0 |
| Juan Ramos, Md, MD | Internal Medicine | Miami, FL | $13,708 | $0 |
| Nabila Bennani, M.d, M.D | Hematology | Rochester, MN | $13,698 | $0 |
| Bradley Haverkos, Md, MD | Internal Medicine | Aurora, CO | $12,099 | $0 |
| Grzegorz Nowakowski, M.d, M.D | Hematology & Oncology | Rochester, MN | $11,900 | $0 |
| Lauren Pinter-Brown, Md, MD | Hematology & Oncology | Los Angeles, CA | $11,773 | $0 |
| William Tse, Md, MD | Hematology & Oncology | Cleveland, OH | $10,802 | $0 |
| Jorge Garcia, Md, MD | Hematology & Oncology | Cleveland, OH | $10,800 | $0 |
| Dr. Marc Garnick, M.d, M.D | Hematology & Oncology | Boston, MA | $10,725 | $0 |
| Ronald Bukowski, Md, MD | Hematology & Oncology | Cleveland, OH | $10,500 | $0 |
| Swaminathan Iyer, M.d, M.D | Hematology & Oncology | Houston, TX | $9,217 | $0 |
| John Glaspy, Md, MD | Hematology & Oncology | Los Angeles, CA | $9,191 | $0 |
| James Yao, M.d, M.D | Medical Oncology | Houston, TX | $9,000 | $0 |
| Dr. Matko Kalac, M.d., Ph.d, M.D., PH.D | Medical Oncology | Orange, CA | $8,634 | $0 |
| Dr. John Sloan, M.d, M.D | Internal Medicine | Boston, MA | $8,571 | $0 |
| Francesca Montanari, Md, MD | Hematology | Greenwich, CT | $8,417 | $0 |
About Acrotech Biopharma LLC
Acrotech Biopharma LLC has made $7.1M in payments to 3,147 healthcare providers, recorded across 7,126 transactions in the CMS Open Payments database. In 2024, the company paid $1.9M. The top product by payment volume is BELEODAQ ($1.3M).
Payments were distributed across 80 medical specialties. The top specialty by payment amount is Hematology & Oncology ($351,709 to 1,045 doctors).
Payment categories include: Food & Beverage ($95,836), Consulting ($661,911), Research ($6.0M), Travel & Lodging ($28,392).
Acrotech Biopharma LLC is associated with 6 products in the CMS Open Payments database, including BELEODAQ, ZEVALIN, and EVOMELA.